journal
MENU ▼
Read by QxMD icon Read
search

Cancer Discovery

journal
https://www.readbyqxmd.com/read/29691237/eradicating-h-pylori-reduces-gastric-cancer-risk
#1
(no author information available yet)
Eliminating the bacterial infection Helicobacter pylori in patients with early gastric cancer may reduce the risk of metachronous disease. In a recent study, eradicating the infection reduced patients' risk of developing a subsequent gastric cancer by almost 50% and, in nearly half of patients, decreased the severity of atrophic gastritis.
April 24, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29678835/the-ezh2-inhibitor-tazemetostat-is-well-tolerated-in-a-phase-i-trial
#2
(no author information available yet)
Tazemetostat has antitumor activity in B-cell non-Hodgkin lymphoma and advanced solid tumors.
April 20, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29678834/from-pluripotent-stem-to-car-t-cells
#3
(no author information available yet)
Within the field of allogeneic chimeric antigen receptor T-cell therapy, La Jolla, CA-based Fate Therapeutics is exploring in vitro differentiation of induced pluripotent stem cells, rather than T cells harvested from donors, as their source material. Preclinical data on the company's off-the-shelf candidate, FT819, look promising so far.
April 20, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29678833/dual-targeting-of-mdmx-and-mdm2-has-antileukemic-activity
#4
(no author information available yet)
A p53-stapled peptide, ALRN-6924, blocks binding to MDMX and MDM2 to activate p53.
April 20, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29678832/a-cancer-germline-antigen-signature-predicts-anti-ctla4-resistance
#5
(no author information available yet)
High expression of the MAGE-A subcluster III is associated with anti-CTLA4 resistance in melanoma.
April 20, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29678831/loss-of-p62-in-adipocytes-promotes-aggressive-prostate-cancer
#6
(no author information available yet)
OPN released from p62-deficient adipocytes enhances fatty-acid oxidation in tumor cells.
April 20, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29669722/warming-cold-melanoma-with-tlr9-agonists
#7
(no author information available yet)
According to data from two ongoing phase I studies for patients with metastatic melanoma whose disease is refractory to PD-1 blockade, the addition of either CMP-001 or SD-101-both investigational TLR9 agonists-could help reverse this resistance.
April 18, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29666060/combo-therapy-for-lung-cancer-extends-survival
#8
(no author information available yet)
The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non-small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in patients who received chemotherapy alone.
April 17, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29666059/vision-for-nci-outlined-by-new-director
#9
(no author information available yet)
Speaking at the American Association for Cancer Research Annual Meeting 2018, Norman "Ned" Sharpless, MD, the new director of the NCI, outlined his vision for the agency and spoke about four areas on which he'd like to focus its efforts: workforce training and development, basic science, "big data," and clinical trials.
April 17, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29666058/early-detection-sequencing-assays-prove-highly-specific
#10
(no author information available yet)
Ultrasensitive DNA-sequencing methods proved more than 99% specific, according to initial findings from GRAIL's Circulating Cell-Free Genome Atlas Study. The data, presented at the American Association for Cancer Research Annual Meeting 2018, demonstrate the feasibility of designing a blood test for early cancer detection.
April 17, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29661759/neoadjuvant-nivolumab-checks-lung-cancer
#11
(no author information available yet)
The PD-1 inhibitor nivolumab given prior to surgical removal of early-stage non-small cell lung cancer is safe and produces a high rate of pathologic response, especially among those with high tumor mutation burden.
April 16, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29661758/high-tmb-predicts-immunotherapy-benefit-in-nsclc
#12
(no author information available yet)
The first data from the phase III CheckMate-227 trial of ipilimumab plus nivolumab for the treatment of non-small cell lung cancer suggests that the two drugs boost progression-free survival in patients with a high tumor mutation burden. After 1 year, progression-free survival was 43% for patients treated with the checkpoint inhibitor combination, compared with 13% for patients treated with chemotherapy.
April 16, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29657137/adjuvant-therapy-for-melanoma-prolongs-rfs
#13
(no author information available yet)
The PD-1 inhibitor pembrolizumab may be an effective adjuvant therapy for patients with stage III melanoma. In a clinical trial, patients who received the drug had a 12-month recurrence-free survival rate of 75.4%, compared with 61% for patients who received a placebo.
April 15, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29657136/blu-667-targets-ret-altered-cancers
#14
(no author information available yet)
Findings from a phase I study indicate that the investigational RET inhibitor BLU-667 is safe and well tolerated, inducing good responses in patients with RET-altered medullary thyroid cancer or non-small cell lung cancer.
April 15, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29657135/precision-targeted-therapy-with-blu-667-for-ret-driven-cancers
#15
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson, Kevin J Wilson, Lucian DiPietro, Paul Fleming, Michael Palmer, Mimi I Hu, Lori Wirth, Marcia S Brose, Sai-Hong Ignatius Ou, Matthew Taylor, Elena Garralda, Stephen Miller, Beni Wolf, Christoph Lengauer, Timothy Guzi, Erica K Evans
The receptor tyrosine kinase, rearranged during transfection (RET), is an oncogenic driver activated in multiple cancers including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and papillary thyroid cancer (PTC). No approved therapies have been designed to target RET; treatment has been limited to multi-kinase inhibitors (MKIs) which can have significant off-target toxicities and limited efficacy. BLU-667 is a highly potent and selective RET inhibitor designed to overcome these limitations...
April 15, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29653955/mechanisms-of-oncogene-induced-replication-stress-jigsaw-falling-into-place
#16
REVIEW
Panagiotis Kotsantis, Eva Petermann, Simon J Boulton
Oncogene activation disturbs cellular processes and accommodates a complex landscape of changes in the genome that contribute to genomic instability, which accelerates mutation rates and promotes tumorigenesis. Part of this cellular turmoil involves deregulation of physiologic DNA replication, widely described as replication stress. Oncogene-induced replication stress is an early driver of genomic instability and is attributed to a plethora of factors, most notably aberrant origin firing, replication-transcription collisions, reactive oxygen species, and defective nucleotide metabolism...
April 13, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29653954/glioblastoma-stem-cell-tumor-cell-cross-talk-drives-gliomagenesis
#17
(no author information available yet)
Reciprocal paracrine signaling between GBM stem cells and GBM cells promotes tumor growth.
April 13, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29653953/the-il15-superagonist-alt-803-plus-nivolumab-has-antitumor-activity
#18
(no author information available yet)
Nivolumab in combination with ALT-803 is tolerable and achieves responses in patients with NSCLC.
April 13, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29653952/larotrectinib-has-antitumor-activity-in-trk-pediatric-solid-tumors
#19
(no author information available yet)
Larotrectinib achieved a 93% response rate in pediatric patients with TRK fusion-positive tumors.
April 13, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29653951/slam-seq-identifies-direct-transcriptional-targets-of-brd4-and-myc
#20
(no author information available yet)
BRD4 activates RNA Pol2-dependent transcription, whereas MYC activates a confined set of target genes.
April 13, 2018: Cancer Discovery
journal
journal
43599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"